TAVNEOS, in combination with rituximab or cyclophosphamide, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). 1
TAVNEOS should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA 1
Product availability may vary by country. Sign up here to receive information when TAVNEOS is available in your market